
Mesoblast Limited: stock overview
Price
$10.89
November 20, 2026Market cap $1.4B
What Ploutos Investor adds for Mesoblast
Part of Ploutos Investor, €9.99 a month
- The full history: 11 fiscal years, from FY2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
In short
Mesoblast had revenue of $120M in the fiscal year to June 30, 2026 and a net loss of $58M. Revenue grew by 74.5% a year on average over the last 5 years. It pays no dividend.
From its SEC filings (latest fiscal year to June 30, 2026) and the price of November 20, 2026.
Its SEC filings- Market cap
- $1.4B
- 130M shares
- P/E
- –
- Revenue, fiscal year
- $120M
- +74.5% a year over 5 years
- Net margin
- -47.8%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+351.4% a year over 2 years
Fiscal years in figures
MESO's revenue, profit, cash flow and dividend with each year-end price, from FY2016 to FY2023, 8 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $1.4B
- $1.4B
- Enterprise value
- –
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- –
- P/B 3-year median: 2.3
- 2.5
- FCF yield 3-year median: -3.6%
- –
- Earnings yield
- –
Profitability
- Gross margin
- 86.1%
- Operating margin
- -47.3%
- Net margin 3-year median: -593.9%
- -47.8%
- ROIC
- -6.5%
- ROIC, 5-year average
- -10.5%
- ROE, fiscal year
- -10.1%
Growth
- Revenue, yearly change
- +599.2%
- EPS, yearly change
- –
- FCF, yearly change
- –
- Revenue, average a year
- +74.5%
The yearly change compares FY2026 with FY2025.
Balance sheet
- Cash
- $103M
- Total debt
- –
- Net cash
- –
- Net debt / EBITDA
- –
- Interest cover
- -2.4x
- Current ratio
- –
Balance sheet of June 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +1.3%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- MESOBLAST LTD
- CIK
- 1345099
- Exchange
- NASDAQ
- Industry (SIC)
- 2836 · Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- June 30
- Latest annual report
- June 30, 2026
- Reporting currency
- USD
- Shares
- 130M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with MESO
- JNJJohnson & Johnson+0,00%Compare with MESO
- ABBVAbbVie+0,00%Compare with MESO
- UNHUnitedHealth+0,00%Compare with MESO
- MRKMerck & Company+0,00%Compare with MESO
- AMGNAmgen+0,00%Compare with MESO
- TMOThermo Fisher Scientific+0,00%Compare with MESO
- ABTAbbott Laboratories+0,00%Compare with MESO
The full analysis
What do Mesoblast's filings show?
These are Mesoblast's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is MESO's market cap?
Mesoblast Limited's market cap is $1.4B, at a price of $10.89 on November 20, 2026 and 130M shares.
How much revenue does MESO have?
Mesoblast had revenue of $120M in the fiscal year to June 30, 2026. Over the last 5 years it changed by +74.5% a year on average.
Does MESO pay a dividend?
No. Mesoblast paid no regular dividend over the last 12 months.
Where do the figures come from?
From Mesoblast Limited's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.